Perfil de la empresa para ULTIMOVACS AS DK1 Acción
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Análisis de IA de ULTIMOVACS AS DK1
Haz clic en cualquier análisis a continuación para obtener información instantánea de la IA de finAgent
Últimos análisis de IA sobre ULTIMOVACS AS DK1
Aún no hay hilos de IA disponibles para esta empresa.